Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
The purpose of this study is to determine if the investigational therapy bb2121 is safe and effective in treating relapsed and refractory multiple myeloma compared to standard regimens.
The study treatment will be either bb2121 or a standard regimen. The choices of the regimens are as per the study doctor’s discretion and dependent on your prior anti-myeloma treatment regimens:
bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T cell therapy. T cells are a kind of white blood cell which form part of your body’s immune system. Your own T cells are not able to recognize multiple myeloma cells. bb2121 therapy involves modifying your own T cells so that they can recognize and destroy the multiple myeloma cells. bb2121 therapy involves modifying your own T cells so that they can recognize a protein called B-Cell Maturation Antigen (BCMA), which your multiple myeloma cells carry on their surface. The bb2121 T cells would then become activated to destroy the multiple myeloma cells. bb2121 therapy is not currently approved for the treatment of relapsed and refractory multiple myeloma and its use in this study is investigational.
In this study, some of your T cells will be collected from your blood in a procedure called leukapheresis. The collected cells will then be modified in a laboratory in the United States. In the laboratory, a new gene will be inserted into your T cells using a genetically modified virus. After approximately 4 to 5 weeks, the modified T cells, now called bb2121 T cells, will be infused back into your blood.
Detailed eligibility will be reviewed when you contact the study team.